Diabetic Peripheral Neuropathy Market is Expected to Expand at a Healthy Growth Rate During the Study Period (2019 -2032)|Key Companies – Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pha

DelveInsight Business Research LLP

DelveInsight’s “Diabetic Peripheral Neuropathy – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of diabetic peripheral neuropathy, with pathophysiology, various kinds of effects of diabetic peripheral neuropathy, factors affecting the disease, etc. The report also provides historical and forecasted diabetic peripheral neuropathy epidemiology, market trends in the 7MM geography, and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Key Highlights for Diabetic Peripheral Neuropathy 

• Key Companies working in the Diabetic Peripheral Neuropathy Market are Lexicon Pharmaceuticals, Glenmark Pharmaceuticals, Regenacy Pharmaceuticals, and many others.

• Key Therapies included in the Diabetic Peripheral Neuropathy market are as follows VM202, LX9211, and many others 

• The Market size for the Diabetic Peripheral Neuropathy market is USD 2,740 million in 2022 and is projected to increase during the forecast period (2023–2032).

• The CAGR for the Diabetic Peripheral Neuropathy market is 6.0%.

Diabetic Peripheral Neuropathy Overview

Diabetic peripheral neuropathy (DPN) is defined as the presence of signs and symptoms of peripheral nerve dysfunction in people with diabetes. It affects nearly 50% of adults with diabetes during their lifetime and is associated with substantial morbidity including pain, foot ulcers, and lower limb amputation.

There are several forms of diabetic peripheral neuropathy. The most common type is distal symmetric polyneuropathy which can be classified as primarily small-fiber, primarily large-fiber, or mixed small and large fiber, and accounts for approximately 75% of all diabetic peripheral neuropathies.

The root cause of diabetic peripheral neuropathy includes, over time blood glucose levels that keep increasing along with high levels of fats, such as triglycerides, in the blood due to diabetes, which results in the damage of nerves. High blood glucose levels can also damage the small blood vessels that nourish nerves with oxygen and nutrients. Without enough oxygen and nutrients, nerves cannot function well.

Although Diabetic Peripheral Neuropathy can occur in many places in the body, the most common symptoms of DPN are abnormal sensations in the toes and feet, including sharp shooting pain, burning, tingling, throbbing, and numbness.

Diabetic Peripheral Neuropathy Epidemiology Insights 

• As per Hicks and Selvin (2019), the prevalence of peripheral neuropathy is estimated to be between 6% and 51% among adults with diabetes depending on age, duration of diabetes, glucose control, and type 1 versus type 2 diabetes. The estimated prevalence of peripheral neuropathy among adults with diabetes in the US is 28%.

• According to Iqbal et al. (2018), the prevalence of peripheral neuropathy in patients with diabetes was 25.8%, as compared to 11.2% in subjects with impaired glucose tolerance (IGT) and 3.9% in control subjects.

• Research by Pfannkuche et al. (2020), the overall peripheral neuropathy prevalence among patients with diabetes is high (40.3%) and patients with type 2 diabetes (42.2%) are more often affected than those with type 1 diabetes (29.1%).

Click here to learn more about the Diabetic Peripheral Neuropathy Market Landscape

The Report Covers the Diabetic Peripheral Neuropathy Epidemiology Segmented by:

• Diabetic Peripheral Neuropathy prevalent cases 

• Diabetic Peripheral Neuropathy type-specific cases 

• Diabetic Peripheral Neuropathy age-specific cases 

Diabetic Peripheral Neuropathy Market Outlook

The Diabetic Peripheral Neuropathy market outlook of the report helps to build a detailed comprehension of the, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Diabetic Peripheral Neuropathy market in 7MM is expected to witness a major change in the study period 2019–2032.

Key Companies Working in the Diabetic Peripheral Neuropathy Market

• Lexicon Pharmaceuticals

• Glenmark Pharmaceuticals

• Regenacy Pharmaceuticals

• Helixmith Pharmaceuticals 

And many others 

Diabetic Peripheral Neuropathy Therapies Covered and Analyzed in the Report

• VM202

• LX9211

And many others 

Learn more about the Key Companies and Emerging Therapies in the Diabetic Peripheral Neuropathy Market

Table of Contents 

1. Key Insights 

2. Diabetic Peripheral Neuropathy Introduction 

3. Executive Summary of Diabetic Peripheral Neuropathy       –     

4. Disease Background and Overview

5. Epidemiology and patient population

6. Diabetic Peripheral Neuropathy Emerging Therapies

7. Diabetic Peripheral Neuropathy Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Diabetic Peripheral Neuropathy Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services